[
    [
        {
            "time": "",
            "original_text": "康泰生物：新冠疫苗驱动业绩增长 13价获批准值得期待",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "业绩增长",
                    "13价",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：新冠疫苗驱动业绩增长 13价获批准值得期待",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物Q3营收同比增141%：乙肝疫苗恢复供应 后期关注13价肺炎疫苗上市进展",
            "features": {
                "keywords": [
                    "Q3营收",
                    "乙肝疫苗",
                    "141%",
                    "13价肺炎疫苗"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物Q3营收同比增141%：乙肝疫苗恢复供应 后期关注13价肺炎疫苗上市进展",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601.SZ)子公司获得乌兹别克斯坦药品再注册证书",
            "features": {
                "keywords": [
                    "子公司",
                    "乌兹别克斯坦",
                    "药品再注册证书"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物(300601.SZ)子公司获得乌兹别克斯坦药品再注册证书",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601.SZ)：无细胞百白破b型流感嗜血杆菌联合疫苗获乌兹别克斯坦药品再注册证书",
            "features": {
                "keywords": [
                    "无细胞百白破b型流感嗜血杆菌联合疫苗",
                    "乌兹别克斯坦",
                    "药品再注册证书"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物(300601.SZ)：无细胞百白破b型流感嗜血杆菌联合疫苗获乌兹别克斯坦药品再注册证书",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601.SZ)：13价肺炎球菌多糖结合疫苗首批产品获得批签发证明",
            "features": {
                "keywords": [
                    "13价肺炎球菌多糖结合疫苗",
                    "批签发证明"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物(300601.SZ)：13价肺炎球菌多糖结合疫苗首批产品获得批签发证明",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：子公司13价肺炎球菌多糖结合疫苗可正式上市销售",
            "features": {
                "keywords": [
                    "13价肺炎球菌多糖结合疫苗",
                    "上市销售"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：子公司13价肺炎球菌多糖结合疫苗可正式上市销售",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康泰生物最新公告：13价肺炎球菌多糖结合疫苗获得批签发证明",
            "features": {
                "keywords": [
                    "13价肺炎球菌多糖结合疫苗",
                    "批签发证明"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物最新公告：13价肺炎球菌多糖结合疫苗获得批签发证明",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601)2021年三季报点评：Q3业绩高增长 研发进入收获期",
            "features": {
                "keywords": [
                    "2021年三季报",
                    "Q3业绩",
                    "高增长",
                    "研发",
                    "收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物(300601)2021年三季报点评：Q3业绩高增长 研发进入收获期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "天风证券：维持康泰生物(300601.SZ)“买入”评级 新冠疫苗带来业绩弹性",
            "features": {
                "keywords": [
                    "天风证券",
                    "买入评级",
                    "新冠疫苗",
                    "业绩弹性"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天风证券：维持康泰生物(300601.SZ)“买入”评级 新冠疫苗带来业绩弹性",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "天风证券维持康泰生物买入评级：PCV13获批上市，新冠疫苗重点关注海外出口",
            "features": {
                "keywords": [
                    "天风证券",
                    "买入评级",
                    "PCV13",
                    "获批上市",
                    "新冠疫苗",
                    "海外出口"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天风证券维持康泰生物买入评级：PCV13获批上市，新冠疫苗重点关注海外出口",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "天风证券：给予康泰生物买入评级",
            "features": {
                "keywords": [
                    "天风证券",
                    "买入评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天风证券：给予康泰生物买入评级",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "国泰君安：新冠疫苗进入业绩兑现期，港股部分标的将受益",
            "features": {
                "keywords": [
                    "国泰君安",
                    "新冠疫苗",
                    "业绩兑现期",
                    "港股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "国泰君安：新冠疫苗进入业绩兑现期，港股部分标的将受益",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]